Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness.
HCV reactivation
Steroid
Sudden deafness
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
23
01
2024
accepted:
28
02
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
Hepatitis C virus (HCV) reactivation has been reported to be caused due to several anticancer drugs and immunosuppressive agents; however, HCV reactivation after steroid monotherapy has rarely been reported. Here, we report the case of a 65-year-old Japanese man with HCV infection who developed HCV reactivation after the administration of prednisolone (PSL) for 6 days for sudden deafness. In the patient history, the positivity for anti-HCV antibody was observed, but serum level of HCV RNA was not measured. Two months after PSL administration, the patient experienced an alanine aminotransferase (ALT) flare and the serum level of HCV RNA was observed to be 6.2 log IU/mL; then, the patient was admitted to our hospital for hepatitis treatment. Based on the clinical course and laboratory findings, the patient was diagnosed with HCV reactivation. Although the ALT levels decreased spontaneously during follow-up, they did not drop to normal range; subsequently, sofosbuvir and ledipasvir treatments were started. A sustained virological response 24 weeks after the end of treatment was achieved. This case study suggests that HCV reactivation with hepatitis flare can occur even after a steroid monotherapy, and doctors should pay attention to HCV reactivation when administering PSL for patients with HCV infection.
Identifiants
pubmed: 38587568
doi: 10.1007/s12328-024-01944-9
pii: 10.1007/s12328-024-01944-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.
doi: 10.1056/NEJM200107053450107
pubmed: 11439948
Wang LS, D’Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844–55.
doi: 10.1002/jmv.24554
pubmed: 27097298
Suda G, Ogawa K, Morikawa K, et al. Treatment of hepatitis C in special populations. J Gastroenterol. 2018;53:591–605.
doi: 10.1007/s00535-017-1427-x
pubmed: 29299684
pmcid: 5910474
Komaki Y, Ozono Y, Nakamura K, et al. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol. 2022;22:210.
doi: 10.1186/s12876-022-02284-z
pubmed: 35484503
pmcid: 9052496
Ozono Y, Nagata K, Hasuike S, et al. Efficacy and safety of sofosbuvir and ledipasvir in japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol. 2017;9:1340–5.
doi: 10.4254/wjh.v9.i36.1340
pubmed: 29359017
pmcid: 5756723
Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–29.
doi: 10.1093/cid/civ344
pubmed: 25935551
Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531–7.
doi: 10.3748/wjg.v17.i12.1531
pubmed: 21472116
pmcid: 3070121
Inoue J, Nakamura T, Masamune A. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies. Viruses. 2019;11:457.
doi: 10.3390/v11050457
pubmed: 31109119
pmcid: 6563158
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.
doi: 10.1016/j.jhep.2017.03.021
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
doi: 10.1002/hep.29800
pubmed: 29405329
Huang M, Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol. 2014;48:189–90.
doi: 10.1097/MCG.0000000000000001
pubmed: 24247815
Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.
doi: 10.1038/nrclinonc.2012.1
pubmed: 22271089
Lok AS, Ward JW, Perrillo RP, et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743–5.
doi: 10.7326/0003-4819-156-10-201205150-00013
pubmed: 22586011
pmcid: 3469313
Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67:36–47.
doi: 10.1002/hep.29344
pubmed: 28653760
Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.
doi: 10.1016/j.jhep.2012.07.031
pubmed: 22871500
Lee HL, Bae SH, Jang B, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017;11:870–7.
doi: 10.5009/gnl16434
pubmed: 28750484
pmcid: 5669604
Mahale P, Thomas SK, Kyvernitakis A, et al. Management of multiple myeloma complicated by hepatitis C virus reactivation: the role of new antiviral therapy. Open Forum Infect Dis. 2015;3:ofv211.
doi: 10.1093/ofid/ofv211
pubmed: 26885541
pmcid: 4751339
Tagawa A, Ogawa T, Tetsuka S, et al. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Mult Scler Relat Disord. 2016;9:155–7.
doi: 10.1016/j.msard.2016.08.003
pubmed: 27645365
Yazici O, Sendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol. 2014;20:6716–24.
doi: 10.3748/wjg.v20.i22.6716
pubmed: 24944464
pmcid: 4051913
Lensen R, Netea MG, Rosendaal FR. Hepatitis C virus reactivation following COVID-19 vaccination – a case report. Int Med Case Rep J. 2021;14:573–6.
pubmed: 34512037
pmcid: 8412816
Mori N, Imamura M, Takaki S, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53:2689–93.
doi: 10.2169/internalmedicine.53.3194
pubmed: 25447651
Sato K, Inoue J, Kakazu E, et al. Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia. Clin J Gastroenterol. 2021;14:1221–6.
doi: 10.1007/s12328-021-01432-4
pubmed: 33983567
Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036–65.
doi: 10.1002/hep.32689
pubmed: 35899384
Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S-20S.
doi: 10.1002/hep.510260703
pubmed: 9305658
Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology. 2010;138:1875–84.
doi: 10.1053/j.gastro.2010.02.004
pubmed: 20152835
Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253–61.
doi: 10.1016/S0192-0561(99)00005-3
pubmed: 10408633
Rumi MG, Filippi FDE, Vecchia CLA, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402–6.
doi: 10.1136/gut.2004.048009
pubmed: 15710990
pmcid: 1774395
Pitini V, Sturniolo G, Arrigo C, et al. HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. Br J Haematol. 2010;150:116–8.
doi: 10.1111/j.1365-2141.2010.08154.x
pubmed: 20230413
Kawano Y, Miyanishi K, Takahashi S, et al. Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma. J Infect Chemother. 2017;23:323–5.
doi: 10.1016/j.jiac.2016.12.008
pubmed: 28109738
Brambilla S, Bellati G, Asti M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology. 1998;27:1678–86.
doi: 10.1002/hep.510270629
pubmed: 9620342
Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.
doi: 10.1002/ajh.21564
pubmed: 19957347
Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis. 2012;44:49–54.
doi: 10.1016/j.dld.2011.07.016
pubmed: 21885355